23 January 2025 ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome
21 January 2025 ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor
13 January 2025 ORYZON announces first patient dosed in NCI-sponsored iadademstat in combination with venetoclax and azacitidine clinical trial in first line acute myeloid leukemia
31 October 2024 ORYZON receives Notice of allowance for patent on novel technology for measuring LSD1 target engagement
24 October 2024 ORYZON reports financial results and corporate update for quarter ended September 30, 2024
1 October 2024 ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder
23 September 2024 ORYZON presents the final data from PORTICO, a global Phase IIb vafidemstat trial in Borderline Personality Disorder (BPD), at the European College of Neuropsycopharmacology (ECNP) congress